公开(公告)号：US20170217888A1

公开(公告)日：2017-08-03

申请号：US15515243

申请日：2015-10-23

申请人： Ono Pharmaceutical Co., Ltd

发明人： Kentaro YASHIRO ,  Daisuke WAKAMATSU ,  Tetsuji SAITO

IPC分类号： C07D213/61

CPC分类号： C07D213/61 ,  A61K31/17 ,  A61K31/341 ,  A61K31/351 ,  A61K31/381 ,  A61K31/4045 ,  A61K31/417 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/505 ,  C07C233/26 ,  C07C233/29 ,  C07C275/32 ,  C07C275/40 ,  C07D209/30 ,  C07D213/40 ,  C07D213/74 ,  C07D233/64 ,  C07D239/26 ,  C07D241/12 ,  C07D271/06 ,  C07D277/28 ,  C07D307/52 ,  C07D309/04 ,  C07D333/20 ,  C07D333/28 ,  C07D413/06

摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.

公开(公告)号：US20180346422A1

公开(公告)日：2018-12-06

申请号：US16059270

申请日：2018-08-09

申请人： Ono Pharmaceutical Co., Ltd.

发明人： Kentaro Yashiro ,  Daisuke WAKAMATSU ,  Tetsuji SAITO

IPC分类号： C07D213/61 ,  C07D307/52 ,  A61K31/17 ,  C07D213/40 ,  C07D209/30 ,  C07D277/28 ,  C07D271/06 ,  C07C233/29 ,  C07C233/26 ,  C07D241/12 ,  C07D413/06 ,  C07D239/26 ,  C07D233/64 ,  C07D333/28 ,  C07D333/20 ,  C07C275/40 ,  C07C275/32 ,  C07D309/04 ,  C07D213/74 ,  A61K31/505 ,  A61K31/4965 ,  A61K31/4545 ,  A61K31/435 ,  A61K31/426 ,  A61K31/4245 ,  A61K31/422 ,  A61K31/417 ,  A61K31/4045 ,  A61K31/381 ,  A61K31/351 ,  A61K31/341

摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.

公开(公告)号：US20200157050A1

公开(公告)日：2020-05-21

申请号：US16752076

申请日：2020-01-24

申请人： Ono Pharmaceutical Co., Ltd.

发明人： Kentaro YASHIRO ,  Daisuke WAKAMATSU ,  Tetsuji SAITO

IPC分类号： C07D213/61 ,  A61K31/17 ,  A61K31/341 ,  A61K31/351 ,  A61K31/381 ,  A61K31/4045 ,  A61K31/417 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/505 ,  C07D213/74 ,  C07D309/04 ,  C07C275/32 ,  C07C275/40 ,  C07D333/20 ,  C07D333/28 ,  C07D233/64 ,  C07D239/26 ,  C07D413/06 ,  C07D241/12 ,  C07C233/26 ,  C07C233/29 ,  C07D271/06 ,  C07D277/28 ,  C07D209/30 ,  C07D213/40 ,  C07D307/52

摘要： The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.

公开(公告)号：US20190135755A1

公开(公告)日：2019-05-09

申请号：US16095370

申请日：2017-04-21

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Kentaro YASHIRO ,  Hideomi KIJIMA ,  Daisuke WAKAMATSU ,  Tetsuji SAITO

IPC分类号： C07D213/61 ,  A61P13/10 ,  A61K9/20

摘要： Crystal polymorphism may exist in a crystalline compound. In the case where crystal polymorphism exists, depending on the crystal form, solubility, dissolution rate, stability against heat, light, humidity, etc. or the like is different. Accordingly, in the production of a pharmaceutical product, it is a very important task to select a crystal form of a drug substance most suitable for a disease indication and a dosage form. The present invention relates to novel crystal forms (A crystal, W crystal, and a hydrate crystal (H crystal)) of a compound I having a strong opening action with respect to KCNQ2-5 channels.

公开(公告)号：US20190127320A1

公开(公告)日：2019-05-02

申请号：US16095374

申请日：2017-04-21

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Kentaro YASHIRO ,  Masashi KATO ,  Tetsuji SAITO ,  Takuya OKADA ,  Daisuke WAKAMATSU ,  Adam James DAVENPORT ,  Christopher Charles STIMSON

IPC分类号： C07C275/32 ,  C07C271/30 ,  A61P13/02

CPC分类号： C07C275/32 ,  A61K31/17 ,  A61K31/27 ,  A61K31/341 ,  A61K31/351 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/505 ,  A61P13/02 ,  A61P13/10 ,  C07C271/30 ,  C07C2602/08 ,  C07D209/14 ,  C07D213/40 ,  C07D213/64 ,  C07D213/74 ,  C07D239/26 ,  C07D241/12 ,  C07D261/08 ,  C07D277/28 ,  C07D307/52 ,  C07D309/04

摘要： An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (1) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (1) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).